All news

B. Riley reiterates buy on Journey Medical, cuts target

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

B. Riley Financial reaffirmed its "buy" rating on Journey Medical (NASDAQ:DERM) while lowering its price target to

Read original source

RILYL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.